Afreximbank: J&J COVID-19 Vaccine Costs Nigeria $7.50 Per Dose

The African Export-Import Bank (Afreximbank), which facilitated
the procurement of the Johnson & Johnson (J&J), Janssen
Pharmaceuticals’ vaccine, says the vaccine cost Nigeria $7.50 as
against $10 per dose.

The bank’s Regional Chief Operating Officer, Abdoulaye Kone,
disclosed this on Thursday in Abuja.

He said the country would procure 29,850,000 doses through the
African Union’s African Vaccine Acquisition Trust (AVAT).

Following the receipt of the shipment of 177,600 doses on
Thursday, Nigeria became one of the earliest beneficiaries of the
supply deal agreed in March to procure 220 million doses for the
continent, with the potential to order another 180 million.

According to data from a clinical trial in South Africa,
J&J’s single dose of the COVID-19 vaccine made by J&J is
highly effective in preventing severe illness and death from the
Delta and Beta variants of the coronavirus.

Mr Kone explained that with the first shipment of 177,600 doses
of the J&J single-dose vaccines, Nigeria would receive over two
million vaccine doses in batches.

“In August, a total of 1,173 132 doses of J&J first batch of
176 000 doses and second batch 997 132 doses. Then deliveries will
continue every month. Afreximbank is delighted to be a part of this
successful breakthrough in Africa,” he stated. “This was also
possible through our partners – Africa Medical Supplies Platform
(AMSP), AVAT, Africa Center for Disease Control & Prevention, and
the AU for their invaluable contribution to achieving this
milestone.”

He disclosed that the rollout of the J&J vaccine began in
August 2021, with Togo the first African country to receive the
shipment from the Africa Union AVAT initiative on August 5.

“The vaccines have been received in Egypt, Lesotho, Angola,
Mauritius, Ghana, and now, Nigeria. The target is to deliver almost
50 million vaccines before the end of December 2021,” he further
noted. “By January 2022, the number of vaccines released will be in
excess of 25 million per month.”

Mr Kone further stated that this would be done in collaboration
with the AMSP and UNICEF providing logistics and delivery services
to the member states.

“The vaccine acquisition is a unique milestone for the African
continent. It is the first time Africa has undertaken a procurement
of this magnitude involving all member states,” he said.

(NAN)

The African Export-Import Bank (Afreximbank), which facilitated
the procurement of the Johnson & Johnson (J&J), Janssen
Pharmaceuticals’ vaccine, says the vaccine cost Nigeria $7.50 as
against $10 per dose.

The bank’s Regional Chief Operating Officer, Abdoulaye Kone,
disclosed this on Thursday in Abuja.

He said the country would procure 29,850,000 doses through the
African Union’s African Vaccine Acquisition Trust (AVAT).

Following the receipt of the shipment of 177,600 doses on
Thursday, Nigeria became one of the earliest beneficiaries of the
supply deal agreed in March to procure 220 million doses for the
continent, with the potential to order another 180 million.

According to data from a clinical trial in South Africa,
J&J’s single dose of the COVID-19 vaccine made by J&J is
highly effective in preventing severe illness and death from the
Delta and Beta variants of the coronavirus.

Mr Kone explained that with the first shipment of 177,600 doses
of the J&J single-dose vaccines, Nigeria would receive over two
million vaccine doses in batches.

“In August, a total of 1,173 132 doses of J&J first batch of
176 000 doses and second batch 997 132 doses. Then deliveries will
continue every month. Afreximbank is delighted to be a part of this
successful breakthrough in Africa,” he stated. “This was also
possible through our partners – Africa Medical Supplies Platform
(AMSP), AVAT, Africa Center for Disease Control & Prevention, and
the AU for their invaluable contribution to achieving this
milestone.”

He disclosed that the rollout of the J&J vaccine began in
August 2021, with Togo the first African country to receive the
shipment from the Africa Union AVAT initiative on August 5.

“The vaccines have been received in Egypt, Lesotho, Angola,
Mauritius, Ghana, and now, Nigeria. The target is to deliver almost
50 million vaccines before the end of December 2021,” he further
noted. “By January 2022, the number of vaccines released will be in
excess of 25 million per month.”

Mr Kone further stated that this would be done in collaboration
with the AMSP and UNICEF providing logistics and delivery services
to the member states.

“The vaccine acquisition is a unique milestone for the African
continent. It is the first time Africa has undertaken a procurement
of this magnitude involving all member states,” he said.

(NAN)